



ANNUAL REPORT

2021

wfh.org


Continuing to support the bleeding disorders community

The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. This continued without interruption in 2021 despite the challenges related to the COVID-19 pandemic.

We work in partnership with healthcare providers (HCPs), governments, and our global network of national member organizations (NMOs) in 147 countries. We provide our NMOs and HCPs with the knowledge and tools they need to identify, support, and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals.

TABLE OF CONTENTS

Our vision and mission	1	Making progress: advocate for safe and sustainable treatment and care	12
Letter from our President and CEO	2	COVID-19: meeting the emerging needs of our global community	14
Our Roadmap to 2025	4	Thank you to our Corporate Partners	16
Our 2021-2025 strategic priorities	5	2021 Financial Report	20
Making progress: identify and diagnose people living with bleeding disorders	6	WFH Board of Directors	24
Making progress: provide adequate care and treatment	8		
Making progress: collect, interpret, and disseminate data	10		





Our vision and mission

Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live.

2021 was a challenging year because of the ongoing COVID-19 pandemic, but our community continued working towards our shared goal of Treatment for All without missing a step. It's this perseverance—combined with our strong global community—that makes us so strong and so inspirational.

—Cesar Garrido, WFH President

”

Letter from our President and CEO

Friends and colleagues,


Who would have imagined that the COVID-19 pandemic would stretch into 2022? Or that a war in Ukraine would put our community there at risk? These events are exerting immense pressure on the global bleeding disorders community. Fortunately, we continue to collectively persevere and move forward. In a world with many challenges, the World Federation of Hemophilia (WFH) continues to be a beacon of hope.



While 2021 was a year with many hurdles—it was also one of major positive change. Our new 2021-2025 strategic priorities provide us with a clear path forward. They define our intended impacts and hold us accountable by establishing clear goals, streamlining our impact measures to better demonstrate progress, and clarifying with whom and through whom we work. They are the result of an extensive consultation process that included over 200 stakeholders from 70 countries.

2021 also saw us realize significant milestones and accomplishments. The WFH Humanitarian Aid Program successfully overcame pandemic-related obstacles. A record of 22,000+ people with hemophilia benefitted from donated treatment products. The Path to Access to Care and Treatment (PACT) Program and the PACT Advocacy Academy were launched. Our Annual Global Survey (AGS) and the World Bleeding Disorders Registry (WBDR) continued to expand. After a multi-year effort, we published the new ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis and Management of VWD, just one year after releasing the WFH Guidelines for the Treatment of Hemophilia, 3rd edition, in 2020.

We would like to thank our volunteers, WFH and WFH USA board members, NMOs and HCP leaders, staff and other stakeholders around the world. Thank you for working together to overcome the challenges we faced in 2021 to get us ever closer to our vision of Treatment for All.




Cesar Garrido
WFH President



Alain Baumann
WFH CEO

Our Roadmap to 2025

Our new strategic framework provides us with a clear path forward. It defines our intended impact and holds us accountable by establishing clear goals, streamlines our impact measures to better demonstrate progress, and clarifies with whom and through whom we work. Our Roadmap to 2025 shows all that we do and why.





Our 2021-2025 Strategic Priorities

- 1** **Redesign our training and education offerings** to maximize impact
- 2** **Set NMO standards of excellence** and support their adoption
- 3** **Strengthen our global advocacy work** to improve access to treatment and care
- 4** **Increase the percentage of people identified and diagnosed** with bleeding disorders through innovation
- 5** **Ensure we have the resources, both financial and human,** to help us achieve our goals



MAKING PROGRESS:

Identify and diagnose people living with bleeding disorders

The WFH estimates that over 75% of expected people living with hemophilia worldwide have not yet been identified and diagnosed. Identification and diagnosis rates are even lower for women and girls with bleeding disorders and for those with VWD and other rare bleeding disorders. Disparities also exist among various regions of the world, with fewer patients identified and diagnosed in lower-income countries. Without accurate diagnosis, those affected have no chance of accessing adequate treatment and care.

75%

of expected people living
with hemophilia worldwide
**have not yet been identified
and diagnosed**



In 2021, the WFH

...helped identify
and diagnose people
living with bleeding
disorders by...

Providing training to improve diagnostic capacity through national and regional laboratory specialist training


Developing and hosting virtual regional laboratory diagnosis workshops where we provided online and hands-on training to laboratory personnel

Increasing laboratory diagnosis effectiveness through our International External Quality Assessment Scheme (IEQAS)

Supporting national outreach projects through our Development Grant Program and our VWD Initiative Program

Patient identification from 2011 to 2020

in Number of people



A man with a beard and a prosthetic leg is shown from the waist up, wearing a grey button-down shirt and grey trousers. He is standing next to a concrete wall and is carefully tending to a large bush of pink daisy-like flowers. His right leg is a prosthetic, and he is leaning slightly forward as he works with the plants. The background is a weathered, grey concrete wall with some peeling paint and a vertical pipe on the left.

MAKING PROGRESS:

Provide adequate care and treatment

The WFH contributes to setting standards of care globally by publishing clinical practice guidelines, and monitoring and communicating treatment-related safety and supply issues, by convening international multi-stakeholder meetings to address challenges in access to safe and effective therapy, and by providing up-to-date and accurate treatment-related information to our community.

The safety and supply of treatment products is a key concern for the bleeding disorders community. The WFH closely monitors product safety, supply, and access; issues advisories related to treatment safety and supply; and monitors the development and regulatory status of new and novel treatments.

In 2021, the WFH

...helped provide adequate care and treatment by...

Working with WFH NMOs, HTC's, and HCPs around the world to gather treatment data

.....

Continuing to donate factor and non-factor replacement therapy through the WFH Humanitarian Aid Program despite the continued challenges of the pandemic

.....

Successfully moving to reach more treaters, in more countries through virtual platforms

.....

Publishing the ASH ISTH NHF WFH 2021 Guidelines on the diagnosis of von Willebrand disease

.....

Holding the WFH Global Summit on Women and Girls with Bleeding Disorders to improve comprehensive clinical management and advocacy efforts globally

.....

Convening the Global Forum on Research and Treatment Products for Bleeding Disorders, an international multi-stakeholder meeting to communicate treatment-related safety and supply issues





MAKING PROGRESS:

Collect, interpret, and disseminate data

WFH research and data collection efforts include the Annual Global Survey, the World Bleeding Disorders Registry, the Gene Therapy Registry, and their accompanying education and capacity building programs. These endeavours provide NMOs and HTC's with the tools to increase their capacity, the framework to collect data on people with bleeding disorders, and the education and training to use that data to conduct research and advocate for better care.



In 2021, the WFH

...helped collect,
interpret, and
disseminate data by...

Expanding the Annual Global Survey (AGS)
to cover more countries and provide more
data to support research and advocacy efforts

.....

**Increasing World Bleeding Disorders Registry
(WBDR) data** to allow more clinicians to
increase the quality of life of patients

.....

**Offering grants to HTC's through the WBDR
Research Support Program (RSP)** to
encourage the use of data for research



MAKING PROGRESS:

Advocate for safe and sustainable treatment and care

The WFH plays a leadership role in global advocacy by convening the global bleeding disorders community to promote equitable access to care for current and emerging treatments. We leverage global and regional advocacy work to enhance the impact of national advocacy initiatives related to policy, care delivery and procurement.





In 2021, the WFH

...advocated for safe and sustainable treatment and care by...

Launching the Path to Access to Care and Treatment (PACT) Program to help advocate for safe and sustainable treatment and care worldwide

.....

Developing the PACT Advocacy Academy—in collaboration with the New York University Robert F. Wagner Graduate School of Public Service (NYU Wagner)—to provide NMO leaders and patient advocates with the necessary knowledge and skills to carry out successful evidence-based advocacy campaigns

.....

Implementing tailored national access plans to increase outreach, diagnosis, and access to sustainable care

.....

Holding the first Global Policy and Access Summit to bring NMO leaders, healthcare providers, national government representatives and Corporate Partners together to share strategies and learnings

.....

Renewing our official non-state actor status with the World Health Organization (WHO) and developing a new three-year collaboration plan

.....

Demonstrating to governments the value of treating people with bleeding disorders (PWBDs) appropriately through the WFH Humanitarian Aid Program

.....

Collaborating with NMOs to support policy and systems change at the national level





COVID-19: Meeting the emerging needs of our global community

COVID-19 pandemic has impacted the global bleeding disorders community in many ways. Access to treatment and care has been affected, there are concerns over expected government budget cuts around the world, isolation has put strain on the psychological wellbeing of members of our community, and there are continued uncertainties with regards to treatment and vaccination. The WFH acted quickly in 2020 to help alleviate some of these pressures, and our work continued last year.





In 2021 the WFH...

Distributed COVID-19 Relief Fund grants to enable WFH NMOs to continue providing programs, services, and safe access treatment and care

Continued to work with donors and logistics companies via our Humanitarian Aid Program to ensure the uninterrupted supply of donated factor to those in need

Provided guidance and practical recommendations on COVID-19 treatment and vaccination—including safety and accessibility considerations



THANK YOU TO OUR CORPORATE PARTNERS

The WFH gratefully acknowledges the generous support of our dedicated partners in 2021. Our Corporate Sponsors are all playing a major role in helping us improve and sustain care for people with bleeding disorders around the world.



GLOBAL PARTNERSHIP RECOGNITION

Global Partnership Recognition is based on our Corporate Partners' overall annual support and recognizes multi-year commitments and alignment with our strategic priorities. We are pleased to acknowledge our 2021 Visionary, Leadership and Collaborating Partners.

Visionary Partners

Sanofi
Sobi

Leadership Partners

Bayer
CSL Behring
F. Hoffmann-La Roche Ltd
Grifols
Pfizer
Takeda

Collaborating Partners

BioMarin
Pharmaceutical Inc.
Biotest
Freeline Therapeutics
GC Pharma
Kedron

LFB
Novo Nordisk
Octapharma
Precision BioLogic
Spark Therapeutics
uniQure

WFH programs and activity support in 2021

CORPORATE PARTNER PROGRAM

Visionary Partners

CSL Behring
Novo Nordisk
Pfizer
Takeda

Leadership Partners

Bayer
Sanofi

Collaborating Partners

BioMarin
Pharmaceutical Inc
F. Hoffmann-La Roche Ltd
Grifols
Octapharma
Sobi
Spark Therapeutics

Contributing Partners

Biotest
GC Pharma
Kedron
LFB
Precision BioLogic
uniQure

WFH HUMANITARIAN AID PROGRAM

Founding Visionary

Sanofi
Sobi

Leadership Contributor

Grifols

Visionary Contributors

Bayer
F. Hoffmann-La Roche Ltd

Contributors

CSL Behring
Takeda

PATH TO ACCESS TO CARE & TREATMENT (PACT) PROGRAM

Leadership Partners

CSL Behring
F. Hoffmann-La Roche Ltd
Pfizer
Sanofi

Collaborating Partners

Biotest
Grifols
Sobi

WORLD BLEEDING DISORDERS REGISTRY

Visionary Partners

Sobi
Takeda

Collaborating Partners

Bayer
CSL Behring
F. Hoffmann-La Roche Ltd
Grifols
Novo Nordisk
Pfizer
Sanofi

SPONSORED PROGRAMS

Development Grant Program

Sanofi

Gene Therapy Education

BioMarin Pharmaceutical Inc.
Pfizer
Spark Therapeutics

International External Quality Assessment Scheme Program (IEQAS)

Novo Nordisk Haemophilia Foundation

Twinning Program

Pfizer

Gene Therapy Round Table

Bayer
BioMarin Pharmaceutical Inc.
CSL Behring
F. Hoffmann-La Roche Ltd
Freeline Therapeutics
Pfizer
Sanofi
Spark Therapeutics
Takeda
uniQure

Global Forum

Bayer
Novo Nordisk
Pfizer
Sanofi
Spark Therapeutics

Musculoskeletal Congress

Gold Sponsors

Sanofi & Sobi
Takeda

Silver Sponsor

Novo Nordisk

Website

eLearning Platform Enhancement

Pfizer

Website Localization

Japanese: Sanofi
Russian: Sobi

Other Sponsored Activities

CSL Behring
Novo Nordisk
Sanofi
Takeda

Other Product Donation

Octapharma

THANK YOU TO OUR DONORS

The WFH gratefully acknowledges the many donors whose generous contributions have ensured more people have access to care, regardless of their type of bleeding disorder, their gender, or where they live. In 2021, the following individuals, corporations, and organizations made financial contributions of CAN\$150 or more to the WFH or WFH USA.

SOLIDARITY FUND

AUSTRALIA	Haemophilia Foundation Australia
AUSTRIA	Österreichische Hämophilie Gesellschaft
BELGIUM	The Belgian Haemophilia Society
BOSNIA AND HERZEGOVINA	Haemophilia Society of Bosnia and Herzegovina
BULGARIA	Bulgarian Haemophilia Association
CANADA	Canadian Hemophilia Society
COSTA RICA	Asociación Costarricense de Hemofilia (ASOHEMO)
CROATIA	Croatian Hemophilia Society
FINLAND	The Finnish Hemophilia Society (SHY)
ICELAND	The Icelandic Hemophilia Society
IRELAND	Irish Haemophilia Society Ltd.
LATVIA	Latvijas Hemofilijas biedrība
LITHUANIA	Lithuania Haemophilia Association
LUXEMBOURG	Association Luxembourgeoise des Hémophiles - ALH
MADAGASCAR	Association pour le Bien-Etre des Hémophiles à Madagascar
MAURITIUS	Haemophilia Association of Mauritius (HAM)
NETHERLANDS	The Netherlands Haemophilia Society - NVHP
SINGAPORE	Haemophilia Society of Singapore
SOUTH AFRICA	South African Haemophilia Foundation
SOUTH KOREA	Korea Hemophilia Foundation
SURINAME	Surinamese Society for Hemophilia Patients
SWEDEN	Swedish Bleeding Disorder Society
SWITZERLAND	Swiss Hemophilia Society
TURKEY	The Hemophilia Society of Turkey
VENEZUELA	Asociación Venezolana para la Hemofilia

SUSAN SKINNER MEMORIAL FUND

Daniel Button
John Button
Hemophilia Foundation of Michigan
Craig Kessler
Pacific Northwest Bleeding Disorders
Amy Renz
Mark Skinner and James Matheson
1 anonymous donor

TRIBUTES

In honour of Alivio
In honour of Joa B.
In honour of Amy Dunn
In honour of Rick Lopez
In honour of Johan Marander
In honour of Frank Schnabel IV
In honour of Mark Skinner
In honour of Audrey Taylor
In honour of the volunteers and staff who
work for those with bleeding
disorders throughout the world
In honour of Toong Youttanakorn
In memory of Anthony Britten
In memory of Damaso García
In memory of Brian, Larkey, Chris
and Brent
In memory of Ashwin Pindoria

DONORS

\$250,000 - \$499,999

Hemophilia of Georgia

\$100,000 - \$249,999

National Hemophilia Foundation
The Hemophilia Alliance

\$50,000 - \$99,999

Glenn and Beatrice Pierce
Logenix International LLC

\$25,000 - \$49,999

The Haemophilia Society

\$10,000 - \$24,999

Mark Skinner and James Matheson

\$5,000 - \$9,999

Canadian Hemophilia Society
Donald and Barbara Goldman
Mary M. Gooley Hemophilia Center
Phillips 66
Frank Schnabel IV and Lillian Schnabel
Wuxi Apptec Sales LLC

\$1,000 - \$4,999

Association française des hémophiles
Alain Baumann
Paula Bell and Rob Christie
Bleeding Disorders Alliance Illinois
Daniel Button
Coalition for Hemophilia B
Colorado Chapter of the National Hemophilia Foundation
Francesco Capaldo
Florida Hemophilia Association
Cesar Garrido
Gateway Hemophilia Association
Great Lakes Hemophilia Foundation
Haemophilia Foundation of New Zealand
Hemophilia Association of the Capital Area
Hemophilia Foundation of Michigan
Hemophilia Foundation of Southern California
Hemophilia of Indiana
Christine Herr
Israeli Hemophilia Association
Craig Kessler
Kate Khair
Barbara Konkle and Peter Kollros
Korea Hemophilia Foundation
Phillip Kucab
Mary Lesh

Lone Star Bleeding Disorders Foundation
Midwest Hemophilia Association
John Murphy
National Hemophilia Network of Japan
Nebraska Chapter of the National Hemophilia Foundation
New England Hemophilia Association
Pacific Northwest Bleeding Disorders
Joseph Pugliese
Rocky Mountain Hemophilia & Bleeding Disorders Association
Edith A. Rosato
Dawn S. Rotellini
Staff of uniQure
Texas Central Hemophilia Association
Kenneth Trader
Tri-State Bleeding Disorder Foundation
Leonard A. Valentino
11 anonymous donors

\$500 - \$999

Bleeding Disorders of South Carolina
Jacie Cunningham
Amy Dunn
Hemophilia Alliance of Maine
Hemophilia Federation (India)
Hemophilia Foundation of Greater Florida
Hemophilia Foundation of Minnesota/Dakotas
Intouch Group
Kentucky Hemophilia Foundation
Jennifer Laliberté
Northern Ohio Hemophilia Foundation
Steven Pipe
Gina Schnabel
Sundar Rajan Selvaraj
William T. Sparrow
The Idaho Chapter of the National Hemophilia Foundation
Virginia Hemophilia Foundation
Simon Widmer
Pamela and Brock Wilton

\$250 - \$499

Alaska Hemophilia Association
Asociación de Hemofílicos del Uruguay
Kimberly Baumann
Per Arne Berg
John and Heather Button
Donna Coffin
Connecticut Hemophilia Society
Randall Curtis
Daniel Doran
Egyptian Society of Hemophilia
Fundación de la Hemofilia (Argentina)

Kerry Grant
Ann Harrington
Hawaii Chapter of the National Hemophilia Foundation
Hemophilia Foundation of Northern California
Peter Hultgren
Peter Jones
Louisiana Hemophilia Foundation
Walter Otieno Mwanda
Margareth Ozelo
Ulrike Reiss
Amy and Allen Renz
Leanna Ringler
Pedro Rodriguez Sanchez
Sean Singh
Sociedad Chilena de la Hemofilia
Southwestern Ohio Hemophilia Foundation
Staff of BioMatrix Specialty Pharmacy
Eric and Marion Stolte
The Hemophilia Society of Turkey
The Malta Bleeding Disorders Society
Andreina Tovar
Edward G. Tuddenham
Dietje E. Fransen van de Putte
West Virginia Chapter of the National Hemophilia Foundation
Western Pennsylvania Bleeding Disorders Foundation
Elvin Thye Seong Yup

\$150 - \$249

Antonio J. Almeida
Christiane Casavant
Ingrid Castro
Brian T. Colvin
Jorge and Debbie de la Riva
Rosa Maria Dueñas - Ríos
Marvin S. Gilbert
Haemophilia Foundation of Nigeria
James Hunt
Marion A. Koerper
Sunil Pindoria
Stephanie Pineda
Corrine Sin Quee-Brown
Catherine Sabourin
Robert Schaub
Joyce Sharon
Chee Wee Tan
Jerome Teitel
Wing Yen Wong
1 anonymous donor

FINANCIAL REPORT

2021

As the worldwide pandemic raged on, the World Federation of Hemophilia (WFH) staff and volunteers remained resilient, learned to work within a new “normal” environment, and continued to deliver our programs and activities. The year ended with a net surplus of \$99 thousand compared to a budgeted net deficit of \$2,251 thousand. This represents an improvement of \$2,350 thousand.



Canadian government support for COVID-19 was a key contributor to this significant result (\$1,432 thousand). The government's offer of financial relief was for programs whose main intention was to keep staff employed, as well as to provide assistance in the form of rent subsidies. We also received an additional \$306 thousand of insurance proceeds for the cancellation of the 2020 World Congress. The strong U.S.A currency (which averaged \$1.25 CAD throughout the year) further contributed to the positive result.

Healthy revenue growth

The Corporate Partners of WFH programs and initiatives continued their committed support with 2021 contributions of \$5,728 thousand, an increase of \$850 thousand (17%) over 2020. A portion of this increase was due to contributions of \$262 thousand towards the biennial WFH Global Forum (GF) and the WFH International Musculoskeletal Congress (MSK), both of which took place in 2021. There was also an increased amount of funding for important new initiatives, such as the Gene Therapy Registry, gene therapy educational endeavours, and the Path to Access to Care and Treatment (PACT) Program.


In 2021, the WFH Humanitarian Aid Program spent \$3,115 thousand (\$2,468 thousand in 2020) against funding received from our Corporate Partners. Despite the continued logistical challenges created by the COVID-19 pandemic, we managed to treat over 22,000 people with hemophilia in 74 emerging countries.

For the WFH Research Program, \$598 thousand was recognized (\$591 thousand in 2020). These funds have enabled the continued success of the World Bleeding Disorder Registry (WBDR)—

enrolling almost 10,000 people with hemophilia from 105 hemophilia treatment centres (HTCs) globally—and the awarding of research grants to HTCs.

The total WFH revenue, before Congresses, Product Donations, and Canada Emergency Wage and Rent Subsidies (CEWS and CERS) reached \$11,521 thousand; \$1,245 thousand (12%) above 2020.

As the WFH has hitherto delivered the biennial WFH World Congress as well as other WFH meetings over a two-year period, it is typical for us to review our results over a two-year cycle. As shown in Figure 1, excluding product donations, 38% of revenues over the two-year cycle are from sponsorships from WFH Corporate Partners; 24% are from restricted programs (Humanitarian Aid and Research Program); 14% are from the Virtual Summit and insurance proceeds; and the remaining 24% are generated from Canadian government relief for COVID-19, self-generating income activities, financial donations, and national member organization (NMO) assessments.



HUMANITARIAN AID PROGRAM **29.8%**

ADMINISTRATION **9.5%**

HEALTHCARE DEVELOPMENT PROGRAMS **22.3%**


GOVERNANCE and COMMUNICATIONS **7.1%**

EDUCATION AND PUBLIC POLICY **15.9%**

FUNDRAISING AND CORPORATE RELATIONS **5.6%**

CONGRESS and VIRTUAL SUMMIT EXPENSES **9.6%**

FLUCTUATION OF FOREIGN EXCHANGE **0.2%**



Expenses during an ongoing pandemic

With the COVID-19 pandemic still necessitating global travel restrictions, most of our activities and events remained virtual. Overall, the activities we held in 2021 resulted in positive variances to our budget, as we had assumed the easing of restrictions and more travel to have taken place. At the same time, we continued to invest in software and hardware to minimize the security risks from the global increase in cybercrime. A major upgrade to our website provided further opportunity to build valuable connections between members of the bleeding disorders community and engage a broader audience.

In aggregate, the healthcare development programs, education and public policy programs, and the WFH Humanitarian Aid Program, continued to represent the largest proportion of expenses with 68% of the expenses incurred over the past two years, as seen in Figure 2. The Virtual Summit, along with expenditures for the 2022 World Congress (spent in 2021), called for a smaller investment (10%) than the World Congress usually requires of WFH expenses, while fundraising and corporate relations expenses represented 6% of the total. Expenses attributed to running the WFH organization included administration at 10%, and governance and communications at 7%.

Humanitarian aid

In spite of the pandemic continuing to impact shipping capacity, keep airfreight rates high, and create in-country barriers to movement, the WFH Humanitarian Aid team found alternative ways to deliver care to those who needed it most. In 2021, we provided treatment to over 22,000 patients in 74 emerging countries. The majority of these donations, worth \$819 million USD, are included in the audited financial statements of WFH USA. The amount included in the financial statements of the WFH is \$200 million.

Year-over-year comparison

The 2021 and 2020 statement of revenues and expenses, illustrated in Figure 3, reflects the fluctuations within a typical two-year cycle where the World Congress/Virtual Summit is held in even years, where the MSK and GF events are held in odd years, and where varying amounts of yearly product donations are received. On the revenue side, before Congresses, CEWS, CERS and Product Donations, there was an excellent growth of \$1,245 thousand. This was largely due to the invaluable \$547 thousand increase in contributions from our Corporate Partners to fund new initiatives such as the Gene Therapy Registry, gene therapy education, and PACT; as well as \$262 thousand for the MSK and GF events held in 2021. Further, the continued growth in the Humanitarian Aid Program with our three major corporate partnerships brought in an additional \$646 thousand. This was offset by the decrease in investment revenues (\$280k) as an overall increase in interest rates negatively affected bonds and caused a significant decline in fixed income returns. This outweighed the steady positive returns shown by equities throughout the year 2021.

The overall spend of \$12,306 thousand in expenses before Congresses and Product Donations—\$2,247 thousand above 2020—reflects the continued efforts of the WFH to support the needs of the global bleeding disorders community, while still living in a pandemic world. This was highlighted by the increase of \$1,291 thousand for the Humanitarian Aid Program that saw the volume of products distributed more than double that of 2020. Healthcare Development Programs grew by \$534 thousand, which included \$153 thousand dedicated to a COVID-19 Relief Fund; \$142 thousand to Global Policy & Advocacy; as well as an increased spend of \$303 thousand for PACT country programs. Further, there was a \$510 thousand increase in Communications expenses, mostly due to the development of our new website.

Looking ahead

As we move forward, the COVID-19 pandemic will continue to have an impact on how we bring about positive outcomes for our community and strong financial results. As evidenced by our upcoming 2022 World Congress, for the foreseeable future, we will deliver a hybrid of virtual and in-person activities to leverage the benefits of both. Although our financial base is currently strong, Congresses, a key source of our funding, are not expected

to bring the surpluses that they have in the past. We will need to rely on the support and flexibility of our corporate and community partners to be able to carry out our important work and to broaden our revenue generation efforts.

As we start to roll out our ambitious new strategic plan, our focus will remain on putting all our resources to work for the benefit of our community and the aim of accomplishing our vision of Treatment for All.

FIGURE 3

Revenues and expenses

(Expressed in Canadian Dollars)

	2021	2020
REVENUES		
Donations	825,540	968,191
Corporate Partner Donations	2,281,626	2,481,690
Corporate Sponsorships	3,446,344	2,396,155
Research Program	597,665	591,382
NMO Assessments	105,593	105,780
Humanitarian Aid Program	3,114,509	2,468,117
Self-Generated Income (Non-Congress)	1,149,693	1,264,715
Total Revenues before Congress, CEWS & CERS and PDs*	11,520,970	10,276,030
Congress/Virtual Summit Revenue and Insurance Proceeds	306,233	3,672,718
Canada Emergency Subsidies (CEWS & CERS)	1,432,413	1,020,732
Product Donations	200,486,376	59,909,908
TOTAL REVENUES	213,745,992	74,879,388
EXPENSES		
Healthcare Development Programs	3,027,882	2,493,443
Education and Public Policy	2,056,671	1,874,917
Humanitarian Aid Program	4,325,180	3,034,496
Governance and Communications	1,147,787	612,309
Fundraising and Corporate Relations	665,568	727,600
Administration	1,095,308	1,259,774
Fluctuation of Foreign Exchange	(11,561)	57,610
Total Expenses before Congress/Virtual Summit and PDs*	12,306,835	10,060,149
Congress and Virtual Summit Expenses	853,375	1,508,973
Product Donations	200,486,376	59,909,908
TOTAL EXPENSES	213,646,586	71,479,030
EXCESS (DEFICIENCY)	99,406	3,400,358

*Product Donations

WFH Board of Directors

We rely on the WFH Board of Directors, WFH staff, and volunteers to support our shared vision of **Treatment for All**.

1



2



3



4



5




6



7



8




9




10



11



12



13




14



15



16



WFH board of directors, members and patron 2020–2022

- | | | | |
|---|--|---|--|
| 1 Cesar Garrido
President
Venezuela | 2 Glenn Pierce
Vice President, Medical
U.S.A. | 3 Barry Flynn
Vice President, Finance
United Kingdom | 4 Carlos Safadi Márquez
Vice President, NMO
Argentina |
| 5 Megan Adediran
Director
Nigeria | 6 Novie Chozie
Director
Indonesia | 7 Saliou Diop
Director
Senegal | 8 Miguel Escobar
Director
U.S.A. |
| 9 Cedric Hermans
Director
Belgium | 10 Barbara Konkle
Director
U.S.A. | 11 Latifa Lamhene
Director
Algeria | 12 Dawn Rotellini
Director
U.S.A. |
| 13 Clive Smith
Director
United Kingdom | 14 Baiba Ziemele
Director
Latvia | 15 Alain Baumann
CEO
Canada | 16 Jan-Willem André de la Porte
Patron
Belgium |

WFH Staff



WFH 2021 HIGHLIGHTS

22,000+

Patients accessing treatment
through the **WFH Humanitarian
Aid Program**

104 **Treatment
centres benefitting**
from the WBDR

156 **Countries reached**
through global
programs and events

World Federation of Hemophilia

1425, boulevard René-Lévesque Ouest
Bureau 1200
Montréal (Québec) H3G 1T7
Canada
T +1 514.875.7944 F +1 514.875.8916

wfh.org

Charitable solicitations for the common purposes of WFH and WFH USA
within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.

